Incubeta Rebrands as New Generation of Digital Partner to Help Businesses Amplify Growth
12.4.2021 12:00:00 EEST | Business Wire | Press release
Leading digital marketing group, Incubeta today announces its new brand identity which unites its specialist teams under one Incubeta brand. The launch of the new positioning is aligned with Incubeta’s emphasis on helping businesses to upgrade their growth through creativity, collaboration and expertise. This rebrand reinforces its commitment to being true performance partners, helping businesses find the right opportunities to accelerate growth.
This vibrant new look for Incubeta represents the personality of the fun, diverse, bright and exciting team that make up the company. A team of more than 440 creators, thinkers, makers, and doers obsessed with finding creative ways to take businesses further, faster. Incubeta’s ‘Upgrade your Growth’ narrative emphasises how the business will grow alongside its clients focusing on expanding its services and products across the entire customer journey, giving clients back control over their data, customers and actions. The Incubeta group has grown 20 fold over the past 7 years, offering fantastic growth opportunities for its people and helping its rising number of clients grow in a complex digital environment.
The unification of its specialisms will ensure Incubeta remains at the forefront of innovation to help businesses unlock the power of digital and amplify growth. It will also position the company as the new generation of digital growth partner – transparent, accountable and agile. Incubeta applies the technical, strategic and creative expertise to help businesses connect with customers, improve performance and extend reach – all in the service of growth.
Lars Lehne, Group CEO of Incubeta comments: “We are thrilled to unveil this new positioning representing the next chapter in our own growth story. Knocking down the silos of marketing and bringing our specialist teams together to build world-class solutions, helps our clients and partners deliver meaningful growth. While the Incubeta family will have a different look, what won’t change is the quality of our services and commitment to delivering outstanding work.”
Incubeta was founded in 2011 when the company Interface made the reverse acquisition of IncuBeta Holdings. It now operates across 17 countries with offices in most major cities across the world. In 2013 the highly successful Net Media Planet (NMPi) was acquired and in 2016 the subsequent acquisition of DQ&A extended the company’s geographical and product growth. This was followed by the acquisition of creative specialists Joystick in 2018 and most recently ecommerce experts Groundswell in March 2021. Today, some of the most innovative brands work with Incubeta, including Google, Amazon, Disney, HBO, Charlotte Tilbury, L'Oréal and Zalando.
ENDS
About Incubeta:
Incubeta is a team of over 440 creators, thinkers, makers and doers working across 17 offices globally to unlock business growth for clients including Google, Hyundai, Netflix, HBO and L'Oréal. Incubeta combines capabilities across the full spectrum of digital disciplines to deliver standout outcomes at every brand touchpoint, from awareness to fulfilment.
Find out more at: incubeta.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210412005054/en/
Contact information
For more information:
Leigh-Ann Hunn
Account Manager, Bluestripe Group
leigh-ann.hunn@bluestripegroup.co.uk
+44 (0)7585575201
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
